Gabriel Ocana Santero - Y Combinator Founder of Exin Therapeutics
Home›Founders›Gabriel Ocana Santero
Gabriel Ocana Santero, Founder of Exin Therapeutics

Gabriel Ocana Santero

CEO at Exin Therapeutics

Neuroscientist with a background in biochemistry and research on gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. Earned MSc in Neuroscience and PhD in Pharmacology at Oxford Uni, focusing on neurodevelopment and the effects of SSRI anti-depressants on early patterns of neural activity. Used neuroAI models at the Gatsby Unit (UCL) to study serotonin’s role in cognition. Currently developing gene therapies for neurological conditions.

Previously at

Gatsby Computational Neuroscience Unit
Gatsby Computational Neuroscience Unit
University of Oxford
University of Oxford
Karolinska Institutet (Stockholm)
Karolinska Institutet (Stockholm)
Institute for Cancer research (Medical University of Vienna)
Institute for Cancer research (Medical University of Vienna)
Alumnus of
University of Oxford
University of Oxford
Universidad Autónoma de Madrid
Universidad Autónoma de Madrid
I.E.S. Marques de Suanzes
I.E.S. Marques de Suanzes